U.S. plans to share AstraZeneca stockpile based on urgent need, pending FDA clearance
WASHINGTON — The White House is making plans to share as many as 60 million doses of COVID-19 vaccine, including 10 million in the coming weeks — but exactly where they will go remains to be seen.
The first 10 million Oxford-AstraZeneca doses, a product not yet approved for use in the U.S., must be reviewed by the Food and Drug Administration before they can be exported, press secretary Jen Psaki said Monday.
“Our national security team, our COVID team, working with the State Department and others — we’re going to assess a range of requests, a range of needs around the world,” she said.
“We expect there to be approximately 10 million doses that could be released, if or when the FDA gives its concurrence, which could happen in the coming weeks. So this is not immediate.”


